(HealthDay)—The addition of bevacizumab to carboplatin/pemetrexed is associated with improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to a study published in the May issue ...
Jun 18, 2019
0
1
In a new study including Yale Cancer Center and Smilow Cancer Hospital researchers, the cancer immunotherapy drug pembrolizumab (Keytruda), increased survival for patients with advanced non-small cell lung cancer (NSCLC), ...
Jun 13, 2019
0
78
As advances in the treatment of non-small cell lung cancer (NSCLC) extend patients' lives, more of these patients are facing a different threat: adverse cardiovascular events, such as heart attacks and heart failure. A new ...
Jun 10, 2019
0
3
Treatment with dabrafenib and trametinib, a drug combination designed to target cancers that harbor certain BRAF gene mutations, was effective in a trial of 35 patients representing 17 distinct tumor types. The single-arm ...
Jun 3, 2019
0
0
Initial results of NRG-LU001 indicate that, although the diabetes agent metformin was well-tolerated by patients, the agent has not clearly improved progression-free survival (PFS) or overall survival (OS) for trial participants ...
Jun 1, 2019
0
4
Crizotinib and entrectinib are both active against ROS1+ non-small cell lung cancer. But which is best? The answer seems easy: Just compare the drugs' clinical trial results. However, not all trials are created equal, and ...
May 30, 2019
0
2
A deep-learning model developed using serial image scans of tumors from patients with non-small cell lung cancer (NSCLC) predicted treatment response and survival outcomes better than standard clinical parameters.
Apr 22, 2019
0
2
Stereotactic Body Radiotherapy (SBRT), a high-dose, precisely delivered radiotherapy, is considered the standard treatment for patients with medically inoperable, node-negative, non-small cell lung cancer (NSCLC). However, ...
Apr 5, 2019
0
0
By any measure, lung cancer patients have it rough.
Mar 21, 2019
0
0
A treatment combination has been provisionally rejected for people with certain types of lung cancer on the NHS in England.
Feb 12, 2019
0
0
